Geitona 2011.
Methods | A cost‐utility and a cost‐effectiveness analysis based on a Markov model, for the Greek NHS |
Participants | Patients with COPD |
Interventions | Indacaterol versus tiotropium or formoterol |
Outcomes | QALYs, life years gained (LYG) and exacerbation rates, cost |
Notes |